Lipschitz, Mikel
Dana-Farber Cancer Institute
3 papers on CoChatORCID 0000-0002-5764-1648
Most cited papers
- Verified
Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity
Jacobson, C. A., Hunter, B. D., Redd, R., Rodig, S. J., Chen, P.-H., Wright, K., Lipschitz, M., Ritz, J., Kamihara, Y., Armand, P., et al. (2020) · Journal of Clinical Oncology
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 352
- Verified
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research
Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer
Cited by 164
- Verified
Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence
Chen, P.-H., Lipschitz, M., Wright, K., Armand, P., Jacobson, C. A., Roberts, Z. J., Rossi, J. M., Bot, A., Go, W. Y., & Rodig, S. J. (2018) · Blood
CAR-T cell therapy researchCancer Immunotherapy and Biomarkers
Cited by 6
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free